Skip to content

Arcus Biosciences

US · RCUS #2467 by market cap Listed 2018
15.62 -0.16 -1.01%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:39

Recent news

  • Rating change
    H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/9/26
  • Rating change
    BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Raises Target Price to $29
    Market Newswire · 2026/8/3
  • Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $45
    Market Newswire · 2026/11/5
  • Rating change
    A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45
    Market Newswire · 2026/8/7
  • Rating change
    Morgan Stanley Downgrades Arcus Biosciences(RCUS.US) to Hold Rating, Maintains Target Price $23
    Market Newswire · 2026/10/22
  • Rating change
    Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/9/10
  • Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/9/30
  • Rating change
    J.P. Morgan Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $41
    Market Newswire · 2026/10/14
  • Rating change
    Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42
    Market Newswire · 2026/8/8
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)
    TipRanks · 2026/9/25
  • Rating change
    BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $29
    Market Newswire · 2026/10/5
  • Rating change
    TD Cowen Initiates Arcus Biosciences(RCUS.US) With Buy Rating
    Market Newswire · 2026/9/16
  • Rating change
    Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/10/20
  • Rating change
    A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $23 to $50
    Market Newswire · 2026/10/21
  • J.P. Morgan Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Cuts Target Price to $40
    Market Newswire · 2026/11/9
  • Rating change
    LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46
    Market Newswire · 2026/9/28
  • Morgan Stanley Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $23
    Market Newswire · 2026/11/6
  • Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/11/5
  • Rating change
    Truist Financial Downgrades Arcus Biosciences(RCUS.US) to Hold Rating, Raises Target Price to $41
    Market Newswire · 2026/10/22
  • Rating change
    Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $40
    Market Newswire · 2026/9/8
  • Rating change
    Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $41
    Market Newswire · 2026/7/23
  • Arcus Biosciences: Offering Expected to Close Oct. 23 RCUS
    Dow Jones · 2026/10/22
  • Rating change
    Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
    Market Newswire · 2026/7/23
  • Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/10/26
  • Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/10/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.

Arcus Biosciences discussion 0 comments

Add a comment